利妥昔单抗联合化疗对高龄弥漫大B细胞性非霍奇金淋巴瘤的疗效探究  被引量:5

Efficacy of rituximab combined with chemotherapy in treatment of elderly diffuse large B-cell non-Hodgkin's lymphoma

在线阅读下载全文

作  者:王思力[1] 黄耘[1] 苏蕊[1] 方志鸿[1] 骆宜茗[1] 徐卫[2] 

机构地区:[1]厦门大学附属第一医院血液科,福建厦门361003 [2]南京医科大学临床医学系,江苏南京210029

出  处:《中国生化药物杂志》2015年第2期110-112,115,共4页Chinese Journal of Biochemical Pharmaceutics

基  金:国家自然科学基金(81170488)

摘  要:目的 探究利妥昔单抗联合化疗对高龄弥漫大B细胞性非霍奇金淋巴瘤(diffuse large B cell lymphoma,DLBCL)的疗效.方法 2005年1月~2009年8月厦门大学附属第一医院接收的高龄DLBCL患者34例,其中10例采用单纯的CEOP化疗方案,24例采用利妥昔单联合化疗的R-CEOP治疗方案.比较2种治疗方案下患者近期疗效、长期随访生存率、不良反应和血清中免疫球蛋白的变化.结果 采用R-CEOP治疗方案的患者近期总有效率为66.7% (16/24)、长期随访生存率第1、2、3年为87.5%、75.0%、54.0%,显著高于CEOP组[近期总有效率50.0% (5/10),第1、2、3年长期随访生存率为81.8%、60.0%、40.0%],差异有统计学意义(P<0.05);不良反应发生率(66.7%)及严重程度低于CEOP组(80.0%),血清中IgG、IgA、IgM发生降低变化的百分比(72.7%、77.3%、72.7%)高于CEOP组(20.0%、30.0%、30.0%),两两比较差异有统计学意义(P<0.05).结论 利妥昔单抗联合化疗对高龄DLBCL疗效确切,高龄DLBCL患者对大部分不良反应可以耐受,但利妥昔单抗易使高龄DLBCL患者血清中免疫球蛋白降低而发生感染.Objective To explore efficacy of rituximab combined with chemotherapy in treatment of elderly diffuse large B-cell non-Hodgkin's lymphoma(DLBCL). Methods From January 2005 to August 2009 in our hospital, 34 cases of elderly patients suffering from DLBCL, 10 cases received CEOP program, and 24 cases received R-CEOP program. Short-term efficacy, long-term follow-up of survival, adverse reactions and serum immunoglobulin of two treatment regimens in patients were compared. Results Short-term efficacy (66. 7% ) and long-term follow-up of survival ( 1,2,3 years was 87.5% ,75.0% ,54. 0% )in patients received R-CEOP treatment programs were significantly higher than patients received CEOP treatment programs( short-term efficacy was 50.0% , 1,2,3 years long-term follow-up of survival was 81.8% ,60. 0% ,40. 0% ) ,which had statistically differences (P 〈 0.05 ). The incidence and severity of adverse reactions( 66.7% ) was lower than CEOP group( 80. 0% ). Reduction percentage of serum IgG, IgA, IgM ( 72.7%, 77.3%, 72.7% ) was higher than CEOP group ( 20. 0%, 30. 0%, 30. 0% ), which had statistically differences ( P 〈 0. 05 ). Conclusion Rituximab combined with chemotherapy in treatment.of diffuse large B-cell lymphoma is effective and adverse reactions are well tolerable, but rituximab is easy to make serum immunoglobulin reduce in elderly DLBCL and rise infection.

关 键 词:利妥昔单抗 高龄弥漫大B细胞性非霍奇金淋巴瘤 

分 类 号:R73[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象